Redeye sees a potential revenue increase for Zubsolv as a result of the new policy introduced in the last days of the Trump administration, allowing almost all physicians to prescribe buprenorphine to treat narcotics addiction. This means easier access to treatment for patients and a positive revenue impact, including revenues from digital therapies.